NYSE - Nasdaq Real Time Price USD

Danaher Corporation (DHR)

265.80 +0.96 (+0.36%)
At close: May 17 at 4:00 PM EDT
265.51 -0.29 (-0.11%)
After hours: May 17 at 7:50 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Steven M. Rales Co-Founder & Chairman -- -- 1951
Mr. Rainer M. Blair President, CEO & Director 5.33M -- 1964
Mr. Mitchell P. Rales Co-Founder & Director -- -- 1957
Mr. Matthew R. McGrew CFO & Executive VP 2.56M -- 1972
Dr. Jose-Carlos Gutierrez-Ramos Ph.D. Senior VP & Chief Science Officer 2.09M -- 1962
Ms. Georgeann F. Couchara Senior Vice President of Human Resources 1.66M -- 1977
Mr. Joakim Weidemanis Executive Vice President 2.76M 6.5M 1969
Mr. Christopher M. Bouda VP & Chief Accounting Officer -- -- --
Mr. John Bedford Vice President of Investor Relations -- -- --
Mr. Brian W. Ellis Senior VP, General Counsel & Chief Compliance Officer 1.93M -- 1967

Danaher Corporation

2200 Pennsylvania Avenue, North West
Suite 800 West
Washington, DC 20037-1701
United States
202 828 0850 https://www.danaher.com
Sector: 
Healthcare
Full Time Employees: 
61,000

Description

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Corporate Governance

Danaher Corporation’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 2; Compensation: 1.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

June 28, 2024 at 12:00 AM UTC

Ex-Dividend Date

July 23, 2024 at 12:30 PM UTC - July 29, 2024 at 12:30 PM UTC

Danaher Corporation Earnings Date

July 26, 2024 at 12:00 AM UTC

Dividend Date

Recent Events

May 16, 2024 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 14, 2024 at 5:40 PM UTC

at Bank of America Healthcare Conference

May 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 23, 2024 at 12:00 PM UTC

Q1 2024 Earnings Call

April 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 27, 2024 at 12:00 AM UTC

ARS: Annual Report to Shareholders

March 5, 2024 at 4:10 PM UTC

at TD Cowen Health Care Conference

February 21, 2024 at 12:00 AM UTC

IRANNOTICE: Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

February 14, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 30, 2024 at 1:00 PM UTC

Q4 2023 Earnings Call

Related Tickers